Research letterTopical Janus kinase inhibitors for the treatment of pediatric alopecia areata
References (5)
- et al.
Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis
J Invest Dermatol
(2014) - et al.
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
JCI Insight
(2016)
Cited by (77)
Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders
2023, Actas Dermo-SifiliograficasTreatment of pediatric alopecia areata: A systematic review
2022, Journal of the American Academy of DermatologyCitation Excerpt :Side effects included diarrhea, headaches, upper respiratory infection, increased appetite, weight gain, fatigue, and transient elevation in transaminases. In 3 reports documenting a total of 18 pediatric patients, 13 responded to topical therapy.102-104 Side effects included application site irritation102 and 1 case of borderline leukopenia in a patient with baseline low white blood cell count.104
Treatment Options for Alopecia Areata in Children and Adolescents
2024, Pediatric DrugsSelectivity, efficacy and safety of JAKinibs: New evidence for a still evolving story
2023, Annals of the Rheumatic DiseasesJanus kinase inhibitors for alopecia areata: A narrative review
2023, Indian Journal of Dermatology, Venereology and Leprology
Drs Craiglow and Sidbury contributed equally.
Funding sources: None.
Conflicts of interest: Dr Brichta is an employee of Chemistry Rx. Dr Craiglow's spouse is an advisory board member, consultant, and principal investigator for Pfizer. Dr Sidbury has acted as an expert witness for Roche and investigator for Pierre Fabre, Scioderm, Anacor, and Sanofi-Regenero. Drs Bayart and DeNiro have no conflicts of interest to report.